| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 28, 2025 | Active | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 28, 2025 | Active | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 28, 2025 | Active | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2025 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2025 | Active | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2025 | Active | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2025 | Active | N/A |
| Arsenic | Health-Based | N/A | 0.027 | Jun 30, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| TTHM | Health-Based | N/A | 0.081 | Jun 30, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 14, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 14, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 14, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 14, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 14, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 14, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 14, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 14, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 14, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 14, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 14, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 14, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 14, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 14, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 14, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 14, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Mar 31, 2025 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Mar 31, 2025 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.027 | Mar 31, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.027 | Mar 31, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.027 | Mar 31, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.027 | Mar 31, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| TTHM | Health-Based | N/A | 0.088 | Mar 31, 2025 | Resolved | N/A |
| TTHM | Health-Based | N/A | 0.088 | Mar 31, 2025 | Resolved | N/A |
| TTHM | Health-Based | N/A | 0.088 | Mar 31, 2025 | Resolved | N/A |
| TTHM | Health-Based | N/A | 0.088 | Mar 31, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 27, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 27, 2025 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.026 | Dec 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.026 | Dec 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.026 | Dec 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.026 | Dec 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.026 | Dec 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| TTHM | Health-Based | N/A | 0.114 | Dec 31, 2024 | Resolved | N/A |
| TTHM | Health-Based | N/A | 0.114 | Dec 31, 2024 | Resolved | N/A |
| TTHM | Health-Based | N/A | 0.114 | Dec 31, 2024 | Resolved | N/A |
| TTHM | Health-Based | N/A | 0.114 | Dec 31, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 29, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 29, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 29, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 29, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 29, 2024 | Active | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 29, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 29, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Dec 4, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Dec 4, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Nov 28, 2024 | Active | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Oct 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Oct 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Oct 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Oct 31, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.022 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.022 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.022 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.022 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Lead and Copper Rule | Health-Based | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Lead and Copper Rule | Health-Based | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Lead and Copper Rule | Health-Based | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| TTHM | Health-Based | N/A | 0.093 | Sep 30, 2024 | Resolved | N/A |
| TTHM | Health-Based | N/A | 0.093 | Sep 30, 2024 | Resolved | N/A |
| TTHM | Health-Based | N/A | 0.093 | Sep 30, 2024 | Resolved | N/A |
| TTHM | Health-Based | N/A | 0.093 | Sep 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 28, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 28, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 28, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 28, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 28, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 28, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 28, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 28, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 28, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.015 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.015 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.015 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.015 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jun 15, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jun 15, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Apr 5, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Apr 5, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Apr 5, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Apr 5, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Mar 30, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Mar 30, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Mar 30, 2024 | Resolved | N/A |
| E. COLI | Monitoring | 0 | N/A | Mar 6, 2024 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Mar 6, 2024 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Mar 6, 2024 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Mar 6, 2024 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| Public Notice | Monitoring | N/A | N/A | Feb 16, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 16, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jan 26, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jan 26, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jan 26, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jan 26, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jan 4, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jan 4, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 29, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 29, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Dec 7, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Dec 7, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Oct 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Oct 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Oct 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Oct 31, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Oct 15, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Oct 15, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Arsenic | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 28, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 28, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Aug 18, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Aug 18, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Aug 18, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Aug 18, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Aug 12, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Aug 12, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 31, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 31, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.013 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.013 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.013 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.013 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.013 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.013 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 20, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 20, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 12, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 12, 2023 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.013 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.013 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.013 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.013 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.013 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.013 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | Feb 28, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 28, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jan 7, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jan 7, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Selenium | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Hair or fingernail loss; numbness in fingers or toes; circulatory problems |
| Selenium | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Hair or fingernail loss; numbness in fingers or toes; circulatory problems |
| Mercury | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Kidney damage |
| Chromium | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Allergic dermatitis |
| Chromium | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Allergic dermatitis |
| Chromium | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Allergic dermatitis |
| Chromium | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Allergic dermatitis |
| Cadmium | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Kidney damage |
| Cadmium | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Kidney damage |
| Cadmium | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Kidney damage |
| Cadmium | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Kidney damage |
| Arsenic | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Beryllium, Total | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Beryllium, Total | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Beryllium, Total | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Beryllium, Total | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Arsenic | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.014 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.014 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.014 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.014 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.014 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.014 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Thallium, Total | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Thallium, Total | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Thallium, Total | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Thallium, Total | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Antimony, Total | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Antimony, Total | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Antimony, Total | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Antimony, Total | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Barium | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Increase in blood pressure |
| Barium | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Increase in blood pressure |
| Barium | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Increase in blood pressure |
| Barium | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Increase in blood pressure |
| Selenium | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Hair or fingernail loss; numbness in fingers or toes; circulatory problems |
| Mercury | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Kidney damage |
| Mercury | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Kidney damage |
| Selenium | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Hair or fingernail loss; numbness in fingers or toes; circulatory problems |
| Mercury | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Kidney damage |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Oct 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Oct 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Oct 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Oct 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2022 | Resolved | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | Aug 22, 2022 | Resolved | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | Aug 22, 2022 | Resolved | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | Aug 22, 2022 | Resolved | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | Aug 22, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 31, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 31, 2022 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jun 24, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jun 24, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jun 15, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jun 15, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jun 15, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jun 15, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jun 10, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jun 10, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jun 10, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jun 10, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2022 | Resolved | N/A |
| Lead and Copper Rule | Health-Based | N/A | N/A | Mar 31, 2022 | Resolved | N/A |
| Lead and Copper Rule | Health-Based | N/A | N/A | Mar 31, 2022 | Resolved | N/A |
| Lead and Copper Rule | Health-Based | N/A | N/A | Mar 31, 2022 | Resolved | N/A |
| Lead and Copper Rule | Health-Based | N/A | N/A | Mar 31, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | N/A |
| Lead and Copper Rule | Health-Based | N/A | N/A | Mar 30, 2022 | Resolved | N/A |
| Lead and Copper Rule | Health-Based | N/A | N/A | Mar 30, 2022 | Resolved | N/A |
| Lead and Copper Rule | Health-Based | N/A | N/A | Mar 30, 2022 | Resolved | N/A |
| Lead and Copper Rule | Health-Based | N/A | N/A | Mar 30, 2022 | Resolved | N/A |
| E. COLI | Monitoring | 0 | N/A | Mar 9, 2022 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Mar 9, 2022 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Mar 9, 2022 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Mar 9, 2022 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 28, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 28, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jan 31, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jan 31, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jan 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jan 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jan 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jan 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jan 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jan 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jan 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jan 31, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jan 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jan 31, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jan 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jan 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jan 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jan 31, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 29, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 29, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Dec 22, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Dec 22, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Dec 22, 2021 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Dec 22, 2021 | Active | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2021 | Resolved | N/A |
| Chlorine | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | Eye and nose irritation; stomach discomfort |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Chlorine | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | Eye and nose irritation; stomach discomfort |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Chlorine | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | Eye and nose irritation; stomach discomfort |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Chlorine | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | Eye and nose irritation; stomach discomfort |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 31, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2021 | Resolved | N/A |
| Chlorine | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | Eye and nose irritation; stomach discomfort |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | N/A |
| Chlorine | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | Eye and nose irritation; stomach discomfort |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | N/A |
| E. COLI | Monitoring | 0 | N/A | Mar 10, 2021 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Mar 10, 2021 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Mar 10, 2021 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Mar 10, 2021 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Mar 10, 2021 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Mar 10, 2021 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Mar 10, 2021 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Mar 10, 2021 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2021 | Resolved | N/A |